{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-117578","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.976167+00:00","generated_at":"2026-05-30T09:47:59.029980+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections","bullets":["Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.","Data show improved survival vs. historical controls; biopsies reveal near absence of tumor cells with dense lymphocyte infiltrates.","Radiologic pseudo-progression observed: post-treatment MRI enhancement despite tumor clearance on histology.","Presented at 2024 IOVC; also disclosed new IL-12/IL-15 multimodal immunotherapy candidate from enLIGHTEN platform."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-117578","json":"https://secwatch.observer/filing/0000950170-24-117578.json","markdown":"https://secwatch.observer/filing/0000950170-24-117578.md","text":"https://secwatch.observer/filing/0000950170-24-117578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/0000950170-24-117578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/cadl-20241028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:47:59.029980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}